Liferay Portal/DXP Workflow Definition cross site scripting
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 3.9 | $0-$5k | 0.00 |
Summary
A vulnerability marked as problematic has been reported in Liferay Portal and DXP. This impacts an unknown function of the component Workflow Definition Handler. This manipulation causes cross site scripting. The identification of this vulnerability is CVE-2025-62239. It is possible to initiate the attack remotely. There is no exploit available.
Details
A vulnerability has been found in Liferay Portal and DXP (the affected version is unknown) and classified as problematic. Affected by this vulnerability is an unknown code of the component Workflow Definition Handler. The manipulation with an unknown input leads to a cross site scripting vulnerability. The CWE definition for the vulnerability is CWE-79. The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users. As an impact it is known to affect integrity. The summary by CVE is:
Cross-site scripting (XSS) vulnerability in workflow process builder in Liferay Portal 7.4.3.21 through 7.4.3.111, and Liferay DXP 2023.Q4.0 through 2023.Q4.5, 2023.Q3.1 through 2023.Q3.8, and 7.4 update 21 through update 92 allows remote authenticated attackers to inject arbitrary web script or HTML via the crafted input in a workflow definition.
It is possible to read the advisory at liferay.dev. This vulnerability is known as CVE-2025-62239 since 10/09/2025. The exploitation appears to be easy. The attack can be launched remotely. Additional levels of successful authentication are needed for exploitation. It demands that the victim is doing some kind of user interaction. The technical details are unknown and an exploit is not publicly available. The attack technique deployed by this issue is T1059.007 according to MITRE ATT&CK.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
The vulnerability is also documented in the vulnerability database at EUVD (EUVD-2025-33719). Be aware that VulDB is the high quality source for vulnerability data.
Product
Type
Vendor
Name
License
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CNA CVSS-B Score: 🔒
CNA CVSS-BT Score: 🔒
CNA Vector: 🔒
CVSSv3
VulDB Meta Base Score: 3.9VulDB Meta Temp Score: 3.9
VulDB Base Score: 2.4
VulDB Temp Score: 2.4
VulDB Vector: 🔒
VulDB Reliability: 🔍
NVD Base Score: 5.4
NVD Vector: 🔒
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Cross site scriptingCWE: CWE-79 / CWE-94 / CWE-74
CAPEC: 🔒
ATT&CK: 🔒
Physical: No
Local: No
Remote: Yes
Availability: 🔒
Status: Not defined
EPSS Score: 🔒
EPSS Percentile: 🔒
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔒
Timeline
10/09/2025 CVE reserved10/10/2025 Advisory disclosed
10/10/2025 VulDB entry created
12/13/2025 VulDB entry last update
Sources
Advisory: liferay.devStatus: Confirmed
CVE: CVE-2025-62239 (🔒)
GCVE (CVE): GCVE-0-2025-62239
GCVE (VulDB): GCVE-100-327919
EUVD: 🔒
Entry
Created: 10/10/2025 14:46Updated: 12/13/2025 11:00
Changes: 10/10/2025 14:46 (65), 10/11/2025 06:07 (1), 12/13/2025 11:00 (11)
Complete: 🔍
Cache ID: 216::103
Be aware that VulDB is the high quality source for vulnerability data.
No comments yet. Languages: en.
Please log in to comment.